Title: Intracellular drug delivery : potential usefulness of engineered Shiga toxin subunit B for targeted cancer therapy
Authors : Luginbühl, Vera
Meier, Nicolas
Kovar, Karin
Rohrer, Jack
Published in : Biotechnology Advances
Volume(Issue) : 36
Issue : 3
Pages : 613
Pages to: 623
Publisher / Ed. Institution : Elsevier
Issue Date: May-2018
License (according to publishing contract) : Licence according to publishing contract
Type of review: Peer review (Publication)
Language : English
Subjects : Antibody-drug conjugates; Biotechnological production; Cancer targeting; Intracellular delivery; Receptor-mediated endocytosis; Shiga toxin; Shiga toxin subunit B; Toxin-drug conjugates
Subject (DDC) : 572: Biochemistry
610: Medicine and health
660.6: Biotechnology
Abstract: A treasure trove of intracellular cancer drug targets remains hidden behind cell membranes. However, engineered pathogen-derived toxins such as Shiga toxins can deliver small or macromolecular drugs to specific intracellular organelles. After binding to ganglioglobotriaosylceramide (Gb3, CD77), the non-toxic subunit B (StxB) of the Shiga-holotoxin is endocytosed and delivers its payload by a unique retrograde trafficking pathway via the endoplasmic reticulum to the cytosol. This review provides an overview of biomedical applications of StxB-based drug delivery systems in targeted cancer diagnosis and therapy. Biotechnological production of the Stx-material is discussed from the perspective of developing efficacious and safe therapeutics.
Departement: Life Sciences und Facility Management
Organisational Unit: Institute of Chemistry and Biotechnology (ICBT)
Publication type: Article in scientific Journal
DOI : 10.1016/j.biotechadv.2018.02.005
ISSN: 0734-9750
URI: https://digitalcollection.zhaw.ch/handle/11475/11523
Appears in Collections:Publikationen Life Sciences und Facility Management

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.